ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

EMPLICITI
Leukemias, lymphomas, and other hematologic cancers
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

EMPLICITI Rx

Generic Name and Formulations:
Elotuzumab 300mg, 400mg; per vial; lyophilized pwd for IV infusion after reconstitution; preservative-free.

Company:
Bristol-Myers Squibb

Therapeutic Use:

Indications for EMPLICITI:

Treatment of multiple myeloma: in combination with lenalidomide and dexamethasone in patients who have received 1–3 prior therapies; or in combination with pomalidomide and dexamethasone in patients who have received ≥2 prior therapies including lenalidomide and a proteasome inhibitor.

Adult:

Give by IV infusion at initial rate of 0.5mL/min (10mg/kg dose) or 3mL/min (20mg/kg dose); may increase stepwise if no reactions develop (see full labeling); max rate 5mL/min. In combination with lenalidomide and dexamethasone: 10mg/kg every week for the first 2 cycles then every 2 weeks thereafter. In combination with pomalidomide and dexamethasone: 10mg/kg every week for first 2 cycles; then starting at cycle 3, give 20mg/kg every 4 weeks. Both: continue until disease progression or unacceptable toxicity. For dosing schedule of lenalidomide, pomalidomide, and dexamethasone: see full labeling. Premedicate with dexamethasone, H1 blocker, H2 blocker, and acetaminophen before each infusion. Dose modifications: see full labeling.

Children:

Not established.

Contraindications:

Consult lenalidomide, pomalidomide, and dexamethasone prescribing information for contraindications before starting therapy (eg, pregnancy).

Warnings/Precautions:

Interrupt infusion if Grade ≥2 infusion reactions occur and manage appropriately. Monitor for development of infections and treat promptly. Monitor for second primary malignancies. Monitor liver function periodically; discontinue if Grade ≥3 elevation of liver enzymes occur; consider resuming after return to baseline values. Pregnancy: not studied. Nursing mothers: not recommended.

Pharmacological Class:

SLAMF7-directed immunostimulatory antibody.

Interactions:

May interfere with correct response classification in SPEP and serum immunofixation assays.

Adverse Reactions:

Fatigue, diarrhea, pyrexia, constipation, cough, peripheral neuropathy, nasopharyngitis, upper respiratory tract infection, decreased appetite, pneumonia, hyperglycemia.

Note:

For lenalidomide, pomalidomide, and dexamethasone specific dosing and safety information, refer to their respective full labeling.

Generic Availability:

NO

How Supplied:

Single-dose vial—1

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs